ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼ : À¯Çüº°, Åõ¿© °æ·Îº°, ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2032³â)
Corticosteroids Market Share, Size, Trends, Industry Analysis Report, By Type (Mineralocorticoids, Glucocorticoids); By Route of Administration; By Application; By Region; Segment Forecast, 2024- 2032
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ¼¼°è ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 85¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Á¶»ç º¸°í¼´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.
õ½Ä, ·ù¸¶Æ¼½º °üÀý¿°, ÇǺΠÁúȯ°ú °°Àº ¸¸¼º ÁúȯÀÇ ±ÞÁõÀº ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀåÀÇ ±âȸ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å´Â °·ÂÇÑ Ç׿°Áõ È¿°ú·Î ÀÎÇØ ÀÌ·¯ÇÑ ÁúȯÀÇ °ü¸®¿¡ ÇʼöÀûÀ̸ç, Àü ¼¼°èÀûÀ¸·Î ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. »ýȰ½À°ü ¿äÀο¡ ÈûÀÔ¾î È¿°úÀûÀÎ Ç׿°Áõ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¸é¼ ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵尡 ÃÖÀü¼±¿¡ ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. Á¦¾à Çõ½ÅÀº ¸Å¿ì Áß¿äÇϸç, ±â¾÷Àº ƯÁ¤ ¸¸¼º Áúȯ¿¡ ´ëÇÑ ¸ÂÃãÇü Á¦Á¦¸¦ °³¹ßÇÏ¿© ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå¿¡¼ Áõ°¡Çϴ ǥÀû Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃæÁ·½Ãų ¼ö ÀÖ½À´Ï´Ù.
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀåÀº »ý¹°ÇÐÀû Á¦Á¦¿Í º´¿ë¿ä¹ýÀÇ ÀáÀçÀû ÅëÇÕÀ¸·Î ÀÎÇÑ ±âȸ¸¦ Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. Ç¥Àû ¸ÞÄ¿´ÏÁòÀ» °¡Áø »ý¹°ÇÐÀû Á¦Á¦´Â ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵åÀÇ ±¤¹üÀ§ÇÑ Ç׿°Áõ ÀÛ¿ë°ú ½Ã³ÊÁö È¿°ú¸¦ ¹ßÈÖÇÏ¿© Ä¡·á °á°ú¸¦ °³¼±ÇÏ°í ºÎÀÛ¿ëÀ» ÁÙÀÌ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ÀÚ°¡¸é¿ªÁúȯ°ú ¿°Áõ¼º ÁúȯÀÇ ¿ªµ¿ÀûÀÎ »óȲ¿¡¼ ´Ù¾çÇÑ Ä¡·á¹ýÀº ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ƯÁ¤ °æ·Î¿¡ ÀÛ¿ëÇÏ´Â »ý¹°ÇÐÀû Á¦Á¦´Â ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å Ä¡·á¿¡ °³ÀÎÈµÈ Â÷¿øÀ» Ãß°¡ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Àü·«Àû Á¶ÇÕÀº »õ·Î¿î Á¦Á¦ ¹× Ä¡·á ¿ä¹ýÀÇ °³¹ßÀ» ÃËÁøÇÏ°í º¹ÀâÇÑ º´Å»ý¸®¸¦ °ü¸®Çϱâ À§ÇÑ º¸´Ù È¿°úÀûÀÌ°í ¸ÂÃãÈµÈ ¼Ö·ç¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå¿¡ Á¡ÁøÀûÀÎ º¯È¸¦ °¡Á®¿À°í Ä¡·á È¿°ú¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.
¿ø°Ý ÀÇ·á¿Í ÀüÀÚ °Ç°Àº ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀåÀ» Çü¼ºÇÏ´Â µ¥ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖÀ¸¸ç »õ·Î¿î ±âȸ¸¦ ¿¾îÁÖ°í ÀÖ½À´Ï´Ù. ÀÇ·áÀÇ µðÁöÅÐÈ´Â ¿ø°Ý ÁøÂûÀ» °¡´ÉÇÏ°Ô Çϰí ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å ó¹æ¿¡ ´ëÇÑ Á¢±ÙÀ» ¿ëÀÌÇÏ°Ô Çß½À´Ï´Ù. ÀÌ·¯ÇÑ Ç÷§ÆûÀº ÀÇ·á ¼ºñ½º Á¦°øÀÚ¿¡°Ô ȯÀÚ¸¦ ¸ð´ÏÅ͸µÇϰí ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ¿ä¹ýÀ» Àû½Ã¿¡ Á¶Á¤ÇÒ ¼ö ÀÖ´Â ±ÇÇÑÀ» ºÎ¿©ÇÕ´Ï´Ù.
EÇコ ¼Ö·ç¼ÇÀº Á¤º¸ È帧À» °£¼ÒÈÇϰí ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵åÀÇ »ç¿ë¹ý°ú ºÎÀÛ¿ë¿¡ ´ëÇÑ È¯ÀÚ ±³À°À» °ÈÇÕ´Ï´Ù. ÀÌ·¯ÇÑ µðÁöÅÐ ÅëÇÕÀº ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀÏ »Ó¸¸ ¾Æ´Ï¶ó ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å Ä¡·áÀÇ º¸±ÞÀ» È®´ëÇÒ ¼ö ÀÖÀ¸¸ç, ƯÈ÷ ÀÇ·á ¼ºñ½º¸¦ Á¦´ë·Î ¹ÞÁö ¸øÇϴ ȯÀڵ鿡°Ô ÇýÅÃÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù. ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀåÀº ¿ø°Ý ÀÇ·á°¡ Á¦°øÇÏ´Â Æí¸®ÇÔ°ú È¿À²¼ºÀ» Ȱ¿ëÇÏ¿© ȯÀÚ Áß½ÉÀÇ Á¢±Ù ¹æ½ÄÀ» ÃËÁøÇϰí Çõ½Å, µ¥ÀÌÅÍ ±â¹Ý ÀλçÀÌÆ®, ÀÇ·á ¼ºñ½º Á¢±Ù¼º °ÈÀÇ ±æÀ» ¿¾îÁÙ °ÍÀÔ´Ï´Ù.
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
2023³â ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀÌµå ºÎ¹®Àº ¹ü¿ë¼º, ¸¸¼º Áúȯ °ü¸® ¹× Ä¡·áÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
2023³â¿¡´Â Àü½Å Èí¼ö ¾ïÁ¦, ±¹¼Ò Ä¡·á, ´Ù¸¥ Ä¡·á¹ý°úÀÇ È£È¯¼ºÀ¸·Î ÀÎÇØ ±¹¼Ò ºÎ¹®ÀÌ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
2023³â ÇǺΠ¾Ë·¹¸£±â ºÎ¹®Àº Ç׿°Áõ Ư¼º, ºü¸¥ Áõ»ó ¿ÏÈ ¹× ±¤¹üÀ§ÇÑ ÀÀ¿ë ºÐ¾ß·Î ÀÎÇØ Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
2023³â, ºÏ¹Ì Áö¿ªÀÌ ±âÁ¸ ±â¾÷, ±ÔÁ¦ ȯ°æ, Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀü ¹× ¿¬±¸ °³¹ß·Î ÀÎÇØ ¼¼°è ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
AbbVie Inc., AstraZeneca plc, Bayer AG, Cipla Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Sanofi S.A. µî ¼¼°è ½ÃÀå ÁøÃâ ±â¾÷ÀÌ Á¸ÀçÇϱ⠶§¹®¿¡ ½ÃÀå °æÀïÀÌ Ä¡¿ÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼·Ð
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå Á¶»ç ¹æ¹ý
Á¦4Àå ¼¼°èÀÇ ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå¿¡ °üÇÑ ÀλçÀÌÆ®
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ¾ÖÇø®ÄÉÀÌ¼Ç ÇöȲ
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå ¿ªÇÐ
¼ºÀå ÃËÁø¿äÀΰú ±âȸ
ÀǾàǰ Á¦Á¦ Áøº¸¿¡ ÀÇÇØ Á¦Ç° ¼ö¿ä°¡ ÀÚ±ØµÉ °ÍÀ¸·Î ¿¹Ãø
°í·ÉÈ Àα¸ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»ó
¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
¿ªÈ¿°ú³ª ºÎÀÛ¿ëÀÌ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ °¡´É¼ºÀÌ ³ô´Ù
PESTEL ºÐ¼®
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå ÀÀ¿ë µ¿Çâ
¹ë·ùüÀÎ ºÐ¼®
COVID-19 °¨¿°ÁõÀÇ ¿µÇ⠺м®
Á¦5Àå ¼¼°èÀÇ ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, Åõ¿© °æ·Îº°
ÁÖ¿ä Á¶»ç °á°ú
¼·Ð
ÈíÀÔ
±¹¼Ò
ÁÖ»ç
°æ±¸
Á¦6Àå ¼¼°èÀÇ ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, À¯Çüº°
ÁÖ¿ä Á¶»ç °á°ú
¼·Ð
¹«±âÁúÄÚ¸£Æ¼ÄÚÀ̵å
´çÁúÄÚ¸£Æ¼ÄÚÀ̵å
Á¦7Àå ¼¼°èÀÇ ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, ¿ëµµº°
ÁÖ¿ä Á¶»ç °á°ú
¼·Ð
ÇǺΠ¾Ë·¹¸£±â
¼Òȱâ°ú
³»ºÐºñÇÐ
±Þ¼º È£Èí±âÁúȯ
·ù¸ÓƼÁò ÀûÀÀÁõ
±âŸ
Á¦8Àå ¼¼°èÀÇ ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, Áö¿ªº°
ÁÖ¿ä Á¶»ç °á°ú
¼·Ð
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå Æò°¡, Áö¿ªº°, 2019-2032³â
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ºÏ¹Ì
ºÏ¹Ì : ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, Åõ¿© °æ·Îº°, 2019-2032³â
ºÏ¹Ì : ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, ¿ëµµº°, 2019-2032³â
ºÏ¹Ì : ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, À¯Çüº°, 2019-2032³â
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ¹Ì±¹
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ij³ª´Ù
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - À¯·´
À¯·´ : ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, Åõ¿© °æ·Îº°, 2019-2032³â
À¯·´ : ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, ¿ëµµº°, 2019-2032³â
À¯·´ : ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, À¯Çüº°, 2019-2032³â
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ¿µ±¹
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ÇÁ¶û½º
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - µ¶ÀÏ
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ÀÌÅ»¸®¾Æ
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ½ºÆäÀÎ
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ³×´ú¶õµå
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ·¯½Ã¾Æ
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ¾Æ½Ã¾ÆÅÂÆò¾ç
¾Æ½Ã¾ÆÅÂÆò¾ç : ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, Åõ¿© °æ·Îº°, 2019-2032³â
¾Æ½Ã¾ÆÅÂÆò¾ç : ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, ¿ëµµº°, 2019-2032³â
¾Æ½Ã¾ÆÅÂÆò¾ç : ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, À¯Çüº°, 2019-2032³â
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - Áß±¹
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - Àεµ
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ¸»·¹À̽þÆ
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ÀϺ»
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - Àεµ³×½Ã¾Æ
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - Çѱ¹
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, Åõ¿© °æ·Îº°, 2019-2032³â
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, ¿ëµµº°, 2019-2032³â
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, À¯Çüº°, 2019-2032³â
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - »ç¿ìµð¾Æ¶óºñ¾Æ
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ¾Æ¶ø¿¡¹Ì¸®Æ®
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - À̽º¶ó¿¤
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ³²¾ÆÇÁ¸®Ä«°øÈ±¹
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ¶óƾ¾Æ¸Þ¸®Ä«
¶óƾ¾Æ¸Þ¸®Ä« : ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, Åõ¿© °æ·Îº°, 2019-2032³â
¶óƾ¾Æ¸Þ¸®Ä« : ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, ¿ëµµº°, 2019-2032³â
¶óƾ¾Æ¸Þ¸®Ä« : ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå, À¯Çüº°, 2019-2032³â
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ¸ß½ÃÄÚ
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ºê¶óÁú
ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ½ÃÀå - ¾Æ¸£ÇîÆ¼³ª
Á¦9Àå °æÀï »óȲ
È®Àå°ú Àμö ºÐ¼®
Á¦ÈÞ/Çù¾÷/ÇÕÀÇ/°ø°³
Á¦10Àå ±â¾÷ °³¿ä
AbbVie Inc.
Astellas Pharma Inc.
AstraZeneca plc
Bausch Health Companies Inc.
Bayer AG
Cipla Limited
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Johnson & Johnson
Lupin Limited
Merck & Co., Inc.
Novartis International AG
Pfizer Inc.
Sanofi S.A.
ksm
The global Corticosteroids market size is expected to reach USD 8.53 billion by 2032, according to a new study by Polaris Market Research. The report "Corticosteroids Market Share, Size, Trends, Industry Analysis Report, By Type (Mineralocorticoids, Glucocorticoids); By Route of Administration; By Application; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The surging prevalence of chronic diseases such as asthma, rheumatoid arthritis, and dermatological disorders propels opportunities in the corticosteroids market. Vital for managing these conditions due to their potent anti-inflammatory properties, corticosteroids witness rising demand globally. Fueled by lifestyle factors, the demand for effective anti-inflammatory solutions positions corticosteroids at the forefront. Pharmaceutical innovation becomes crucial, presenting companies with the prospect of developing tailored formulations for specific chronic diseases, meeting the growing need for targeted therapeutic solutions in the corticosteroids market.
The corticosteroids market is capitalizing on opportunities presented by the potential integration of biologics and combination therapies. Biologics, with targeted mechanisms, synergize with the broad anti-inflammatory actions of corticosteroids, aiming for enhanced therapeutic outcomes and reduced side effects. In the dynamic landscape of autoimmune and inflammatory disorders, diversified treatment modalities are crucial. Biologics, addressing specific pathways, add a personalized dimension to corticosteroid treatments. This strategic combination fosters the development of novel formulations and treatment regimens, offering more effective and tailored solutions for managing complex conditions, marking a progressive shift in the corticosteroids market and promising improved therapeutic efficacy.
Telemedicine and E-Health are increasingly pivotal in shaping the corticosteroids market, opening novel opportunities. The digital transformation in healthcare allows for remote consultations, facilitating easier access to corticosteroid prescriptions. These platforms empower healthcare providers to monitor patients, ensuring timely adjustments to corticosteroid regimens.
E-Health solutions streamline information flow, enhancing patient education on corticosteroid usage and side effects. This digital integration not only boosts patient adherence but also broadens the reach of corticosteroid therapies, particularly benefiting underserved populations. The corticosteroids market capitalizes on the convenience and efficiency introduced by telemedicine, fostering a patient-centric approach and creating avenues for innovation, data-driven insights, and enhanced healthcare accessibility.
Corticosteroids Market Report Highlights
In 2023, the glucocorticoids segment accounted for significant market share owing to versatility, management of chronic diseases, and therapeutic advancements.
In 2023, the topical segment accounted for significant market share owing to reduced systemic absorption, localized treatment, and compatibility with other therapies.
In 2023, the skin allergies segment held significant revenue share owing to anti-inflammatory properties, quick symptomatic relief, and wide range of applications.
In 2023, North America region dominated the global market due to established players, regulatory environment, ongoing technological advancements, and research and development.
The market is highly competitive owing to the existence of market players with a global presence, including AbbVie Inc., AstraZeneca plc, Bayer AG, Cipla Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, and Sanofi S.A. among others.
Polaris Market Research has segmented the Corticosteroids market report based on type, route of administration, application, and region:
Corticosteroids, Type Outlook (Revenue - USD Billion, 2019 - 2032)
Mineralocorticoids
Glucocorticoids
Corticosteroids, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)
Inhaled
Topical
Injectable
Oral
Corticosteroids, Application Outlook (Revenue - USD Billion, 2019 - 2032)
Skin Allergies
Gastroenterology
Endocrinology
Acute Respiratory Diseases
Rheumatology Indications
Others
Corticosteroids, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
North America
U.S.
Canada
Europe
France
Germany
UK
Italy
Netherlands
Spain
Russia
Asia Pacific
Japan
China
India
Malaysia
Indonesia
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Table of Contents
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
3. Research Methodology
3.1. Overview
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Global Corticosteroids Market Insights
4.1. Corticosteroids Market - Application Snapshot
4.2. Corticosteroids Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Advancements in drug formulations are projected to spur the product demand
4.2.1.2. Rising aging population is expected to drive market growth
4.2.2. Restraints and Challenges
4.2.2.1. Adverse reactions and side effects are likely to impede the market growth
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Corticosteroids Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global Corticosteroids Market, by Route of Administration
5.1. Key Findings
5.2. Introduction
5.2.1. Global Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
5.3. Inhaled
5.3.1. Global Corticosteroids Market, by Inhaled, by Region, 2019-2032 (USD Billion)
5.4. Topical
5.4.1. Global Corticosteroids Market, by Topical, by Region, 2019-2032 (USD Billion)
5.5. Injectable
5.5.1. Global Corticosteroids Market, by Injectable, by Region, 2019-2032 (USD Billion)
5.6. Oral
5.6.1. Global Corticosteroids Market, by Oral, by Region, 2019-2032 (USD Billion)
6. Global Corticosteroids Market, by Type
6.1. Key Findings
6.2. Introduction
6.2.1. Global Corticosteroids Market, by Type, 2019-2032 (USD Billion)
6.3. Mineralocorticoids
6.3.1. Global Corticosteroids Market, by Mineralocorticoids, by Region, 2019-2032 (USD Billion)
6.4. Glucocorticoids
6.4.1. Global Corticosteroids Market, by Glucocorticoids, by Region, 2019-2032 (USD Billion)
7. Global Corticosteroids Market, by Application
7.1. Key Findings
7.2. Introduction
7.2.1. Global Corticosteroids Market, by Application, 2019-2032 (USD Billion)
7.3. Skin Allergies
7.3.1. Global Corticosteroids Market, by Skin Allergies, By Region, 2019-2032 (USD Billion)
7.4. Gastroenterology
7.4.1. Global Corticosteroids Market, by Gastroenterology, By Region, 2019-2032 (USD Billion)
7.5. Endocrinology
7.5.1. Global Corticosteroids Market, by Endocrinology, By Region, 2019-2032 (USD Billion)
7.6. Acute Respiratory Diseases
7.6.1. Global Corticosteroids Market, by Acute Respiratory Diseases, By Region, 2019-2032 (USD Billion)
7.7. Rheumatology Indications
7.7.1. Global Corticosteroids Market, by Rheumatology Indications, By Region, 2019-2032 (USD Billion)
7.8. Others
7.8.1. Global Corticosteroids Market, by Others, By Region, 2019-2032 (USD Billion)
8. Global Corticosteroids Market, by Geography
8.1. Key findings
8.2. Introduction
8.2.1. Corticosteroids Market Assessment, By Geography, 2019-2032 (USD Billion)
8.3. Corticosteroids Market - North America
8.3.1. North America: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.3.2. North America: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.3.3. North America: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.3.4. Corticosteroids Market - U.S.
8.3.4.1. U.S.: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.3.4.2. U.S.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.3.4.3. U.S.: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.3.5. Corticosteroids Market - Canada
8.3.5.1. Canada: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.3.5.2. Canada.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.3.5.3. Canada: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.4. Corticosteroids Market - Europe
8.4.1. Europe: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.4.2. Europe.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.4.3. Europe: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.4.4. Corticosteroids Market - UK
8.4.4.1. UK: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.4.4.2. UK.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.4.4.3. UK: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.4.5. Corticosteroids Market - France
8.4.5.1. France: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.4.5.2. France.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.4.5.3. France: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.4.6. Corticosteroids Market - Germany
8.4.6.1. Germany: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.4.6.2. Germany.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.4.6.3. Germany: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.4.7. Corticosteroids Market - Italy
8.4.7.1. Italy: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.4.7.2. Italy.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.4.7.3. Italy: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.4.8. Corticosteroids Market - Spain
8.4.8.1. Spain: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.4.8.2. Spain.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.4.8.3. Spain: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.4.9. Corticosteroids Market - Netherlands
8.4.9.1. Netherlands: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.4.9.2. Netherlands.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.4.9.3. Netherlands: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.4.10. Corticosteroids Market - Russia
8.4.10.1. Russia: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.4.10.2. Russia.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.4.10.3. Russia: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.5. Corticosteroids Market - Asia Pacific
8.5.1. Asia Pacific: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.5.2. Asia Pacific.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.5.3. Asia Pacific: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.5.4. Corticosteroids Market - China
8.5.4.1. China: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.5.4.2. China.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.5.4.3. China: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.5.5. Corticosteroids Market - India
8.5.5.1. India: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.5.5.2. India.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.5.5.3. India: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.5.6. Corticosteroids Market - Malaysia
8.5.6.1. Malaysia: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.5.6.2. Malaysia.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.5.6.3. Malaysia: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.5.7. Corticosteroids Market - Japan
8.5.7.1. Japan: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.5.7.2. Japan.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.5.7.3. Japan: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.5.8. Corticosteroids Market - Indonesia
8.5.8.1. Indonesia: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.5.8.2. Indonesia.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.5.8.3. Indonesia: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.5.9. Corticosteroids Market - South Korea
8.5.9.1. South Korea: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.5.9.2. South Korea.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.5.9.3. South Korea: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.6. Corticosteroids Market - Middle East & Africa
8.6.1. Middle East & Africa: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.6.2. Middle East & Africa.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.6.3. Middle East & Africa: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.6.4. Corticosteroids Market - Saudi Arabia
8.6.4.1. Saudi Arabia: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.6.4.2. Saudi Arabia.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.6.4.3. Saudi Arabia: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.6.5. Corticosteroids Market - UAE
8.6.5.1. UAE: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.6.5.2. UAE.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.6.5.3. UAE: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.6.6. Corticosteroids Market - Israel
8.6.6.1. Israel: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.6.6.2. Israel.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.6.6.3. Israel: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.6.7. Corticosteroids Market - South Africa
8.6.7.1. South Africa: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.6.7.2. South Africa.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.6.7.3. South Africa: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.7. Corticosteroids Market - Latin America
8.7.1. Latin America: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.7.2. Latin America.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.7.3. Latin America: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.7.4. Corticosteroids Market - Mexico
8.7.4.1. Mexico: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.7.4.2. Mexico.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.7.4.3. Mexico: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.7.5. Corticosteroids Market - Brazil
8.7.5.1. Brazil: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.7.5.2. Brazil.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.7.5.3. Brazil: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
8.7.6. Corticosteroids Market - Argentina
8.7.6.1. Argentina: Corticosteroids Market, by Route of Administration, 2019-2032 (USD Billion)
8.7.6.2. Argentina.: Corticosteroids Market, by Application, 2019-2032 (USD Billion)
8.7.6.3. Argentina: Corticosteroids Market, by Type, 2019-2032 (USD Billion)
9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
10.1. AbbVie Inc.
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Development
10.2. Astellas Pharma Inc.
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Development
10.3. AstraZeneca plc
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Development
10.4. Bausch Health Companies Inc.
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Development
10.5. Bayer AG
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Development
10.6. Cipla Limited
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Development
10.7. Eli Lilly and Company
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Development
10.8. F. Hoffmann-La Roche Ltd.
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Development
10.9. GlaxoSmithKline plc
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Recent Development
10.10. Johnson & Johnson
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Recent Development
10.11. Lupin Limited
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. Product Benchmarking
10.11.4. Recent Development
10.12. Merck & Co., Inc.
10.12.1. Company Overview
10.12.2. Financial Performance
10.12.3. Product Benchmarking
10.12.4. Recent Development
10.13. Novartis International AG
10.13.1. Company Overview
10.13.2. Financial Performance
10.13.3. Product Benchmarking
10.13.4. Recent Development
10.14. Pfizer Inc.
10.14.1. Company Overview
10.14.2. Financial Performance
10.14.3. Product Benchmarking
10.14.4. Recent Development
10.15. Sanofi S.A.
10.15.1. Company Overview
10.15.2. Financial Performance
10.15.3. Product Benchmarking
10.15.4. Recent Development